A phase 1 basket trial, enrolling 77 patients with pretreated advanced solid tumors, reported an ORR of 13%, which included PRs in 2 patients with RCC.69 Volrustomig (MEDID5752), a bispecific antibody targeting CTLA-4 and PD-1, was evaluated in an early phase study for untreated advanced ccRCC. Here, CTLA4 is linked to nonpapillary renal cell carcinoma.